THERAPY OF HYPOPLASTIC ANEMIA WITH BONE MARROW TRANSPLANTATION

Journal Article · Sat Jul 01 04:00:00 EDT 1961 · Arch. Internal Med.

DOI:https://doi.org/10.1001/archinte.1961.03620070025004· OSTI ID:4735925

McFarland, W; Granville, N; Schwartz, R; Oliner, H; Misra, D K; Dameshek, W

Twerty cases of aplastic anemia were treated with infusions of homologous bone marrow, and their course compared with the results obtained in 17 patients treated with measures other than marrow infusions. No differences in the overall survival were found between the group treated with bone marrow and the control group. Splenectomy had no discernible, statistical effect on the survival of either group, but there were 3 cases in which a dramatic effect took place following splenectomy which was done about 2 weeks after bone marrow transplantation; thus the role of the spleen in the acceptance of a marrow graft remains uncertain. Patients who received marrow from closely related donors appeared to respond significantly better than those who received marrow obtained from unrelated donors. The dose of marrow cells and route of adminlstration (intravenously or directly into the medullary cavity) seemed unrelated to eventual recovery in the treated group. The use of high doses of corticosteroids, in an attempt to allay the homograft reaction, represerted a genuine hazard to the leukopenic, aplastic patient with respect to the incidence of fatal infection. Certain patients treated with bone marrow infusions derived both immediate, objective hematologic effects and sustained benefits from the treatment. Some of these patients are apparertly cured. The mechanisms of the immediate salutary effects occurring in some cases following bone marrow infusions are obscure. Although the value of bone marrow infusions in the treatment of hypoplastic anemia is uncertain, sufficient indications of possible benefit are present to warrant continuation of the study. More exact data are particularly needed with respect to actual, although temporary, bone marrow transplartation, and the combined effects of marrow infusion and splenectomy. (auth)

• Research Organization: Tufts Univ., Medford, Mass.
• Sponsoring Organization: USDOE
• NSA Number: NSA-17-007911
• OSTI ID: 4735925
• Journal Information: Arch. Internal Med., Journal Name: Arch. Internal Med. Vol. Vol: 108
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

ANEMIA
BIOLOGY AND MEDICINE
BONE MARROW
CORTICOSTEROIDS
HORMONES
INFECTIONS
LEUCOCYTES
LIFETIME
MAN
MEDICINE
QUANTITY RATIO
RECOVERY
SPLEEN
STEROIDS
SURGERY
TRANSPLANTS